Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Vidaza 25 mg/ml powder for suspension for injection, Gilteritinib
Astellas Pharma GmbH
Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets
The George Institute
Acute Myeloid Leukemia, ONCOLOGY
1 trial -
Viltolarsen
Lacuna Pharma Pty Ltd
Duchenne Muscular Dystrophy (DMD)
1 trial -
Vincristine placebo, VINCRISTINE , Polivy 140 mg powder for concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion
Hoffmann-La Roche
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
1 trial -
Viread 245 mg film-coated tablets, Viread 123 mg film-coated tablets, Viread 204 mg film-coated tablets, PTM Tenofovir DF, Viread 163 mg film-coated tablets, Viread 33 mg/g granules
Gilead Sciences Pty Limited
Hepatitis B Infection
1 trial -
Vocabria 600 mg prolonged-release suspension for injection, REKAMBYS 900 mg prolonged-release suspension for injection
ViiV Healthcare Pty Ltd
HIV Infections
1 trial -
Vortioxetine 10 mg/day
Takeda
Depressive Disorder, Major
2 trials -
Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection
BioMarin Pharmaceutical Australia Pty Ltd
Hypochondroplasia
1 trial -
Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection
BioMarin Pharmaceutical Australia Pty Ltd
Achondroplasia
1 trial -
Voxzogo 1.2 mg powder and solvent for solution for injection, powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection
BioMarin Pharmaceutical Australia Pty Ltd
Hypochondroplasia
1 trial -
Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo
Astellas Pharma GmbH
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma
1 trial -
Vyvgart 1 000 mg solution for injection
argenx
Generalized Myasthenia Gravis
1 trial -
Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo PH20 SC
argenx
Ocular Myasthenia Gravis
1 trial -
Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod
argenx
Thyroid Eye Disease (TED)
1 trial -
Vyvgart 20 mg/mL concentrate for solution for infusion
argenx
Generalized Myasthenia Gravis
1 trial -
Vyvgart 20 mg/mL concentrate for solution for infusion
argenx
Generalized Myasthenia Gravis (gMG)
1 trial -
Walvax PCV13-TT
Biotech Pharmaceutical Co.,
Pneumococcal Disease, Invasive
1 trial -
Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, KAI-9531
Kailera Therapeutics
Obesity
1 trial -
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143
NovoThirteen
Participants with overweight or obesity, and type 2 diabetes
1 trial -
Wegovy 2.4 mg solution for injection in pre-filled pen, Rybelsus 14 mg tablets, Clopidogrel Medreg 75 mg filmom obalenΓ© tablety, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Wegovy 1.7 mg solution for injection in pre-filled pen, Acetylsalicylic acid Krka 100 mg enterotabletter, Rybelsus 3 mg tablets
Istituto Gentili S.r.l.
Diabetes Mellitus, Cardiovascular disease, Overweight (BMI β₯27 kg/mΒ²), Obesity (BMIβ₯30kg/m2)
1 trial -
White opaque capsule filled with a white to off- white powder, eRapa
Biodexa Pharmaceuticals Plc
Familial adenomatous polyposis (FAP)
1 trial -
XALKORI 200 mg hard capsules, Alecensa 150 mg hard capsules, XALKORI 200 mg hard capsules, Alectinib (Alecensa), XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules
Hoffmann-La Roche
Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
1 trial -
XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)
Bristol-Myers Squibb Australia Pty Ltd
Non small cell lung cancer (NSCLC)
1 trial -
XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek 100 mg hard capsules, Rozlytrek, Rozlytrek 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek
Hoffmann-La Roche
Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources